![]() |
Volumn 4, Issue 2, 2008, Pages 68-69
|
Recommendations for the diagnosis and treatment of dense deposit disease
|
Author keywords
Dense deposit disease; Diagnosis; Membranoproliferative glomerulonephritis type II; Treatment
|
Indexed keywords
ECULIZUMAB;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
NEPHRITIC FACTOR;
RITUXIMAB;
STEROID;
SULODEXIDE;
DENSE DEPOSIT DISEASE;
GENE MUTATION;
GLOMERULUS BASEMENT MEMBRANE;
HUMAN;
KIDNEY BIOPSY;
KIDNEY TRANSPLANTATION;
MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;
NONHUMAN;
NOTE;
OUTCOME ASSESSMENT;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
ANIMALS;
ANTIBODIES, MONOCLONAL;
COMBINED MODALITY THERAPY;
COMPLEMENT FACTOR H;
COMPLEMENT PATHWAY, ALTERNATIVE;
DISEASE MODELS, ANIMAL;
DISEASE PROGRESSION;
EDUCATION, MEDICAL, CONTINUING;
FEMALE;
GENETIC MARKERS;
GENETIC PREDISPOSITION TO DISEASE;
GLOMERULAR BASEMENT MEMBRANE;
GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE;
HUMANS;
ICELAND;
KIDNEY FAILURE, CHRONIC;
KIDNEY FUNCTION TESTS;
MALE;
PLASMA EXCHANGE;
PRACTICE GUIDELINES AS TOPIC;
PROGNOSIS;
RISK ASSESSMENT;
SEVERITY OF ILLNESS INDEX;
TREATMENT OUTCOME;
|
EID: 38749091674
PISSN: 17458323
EISSN: 17458331
Source Type: Journal
DOI: 10.1038/ncpneph0678 Document Type: Note |
Times cited : (2)
|
References (4)
|